IMMNOV.ST - Immunovia AB (publ)

Stockholm - Stockholm Real Time Price. Currency in SEK
181.00
+9.60 (+5.60%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous Close171.40
Open171.40
Bid178.40 x 0
Ask181.00 x 0
Day's Range171.20 - 181.00
52 Week Range75.50 - 199.00
Volume28,209
Avg. Volume30,909
Market Cap3.135B
Beta2.56
PE Ratio (TTM)N/A
EPS (TTM)-2.67
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire5 days ago

    Linköping University Hospital Second Swedish Site in Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer

    Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer. LUND and LINKÖPING, Sweden, May 22, 2018 /PRNewswire/ -- Immunovia AB today announced that Linköping University Hospital is to participate in PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s innovative blood test, IMMray™ PanCan-d, the study will analyze more than thousand individuals over three years across sites in Sweden, the US and Europe already offering FPC screening programs.

  • PR Newswire5 days ago

    Linköping University Hospital Second Swedish Site in Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer

    Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer. LUND and LINKÖPING, Sweden , May 22, 2018 /PRNewswire/ -- Immunovia AB today announced that ...

  • ACCESSWIRE2 months ago

    Edison Issues Outlook on Immunovia (IMMUNOV)

    LONDON, UK / ACCESSWIRE / March 22, 2018 / Immunovia (STOCKHOLM: IMMNOV) is preparing to market its IMMray PanCan-d for self-pay patients at high risk of pancreatic cancer (PC) in Q418, after preparatory ...

  • PR Newswire2 months ago

    Immunovia Announces Financial Targets

    The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018. The financial targets show that the Company's goal is to reach SEK 250-300 million in turnover in 2021 based on "self-pay"-sales and a turnover of SEK 800-1,000 million in 2023 including self-pay and reimbursements in Europe and the US. Immunovia performs clinical validation studies for the commercialization of IMMray™ PanCan-d, which may be the first blood-based test for early diagnosis of pancreatic cancer.

  • PR Newswire2 months ago

    Immunovia Announces Financial Targets

    The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018. The financial targets show that the Company's goal is to reach SEK 250-300 million in turnover in 2021 based on "self-pay"-sales and a turnover of SEK 800-1,000 million in 2023 including self-pay and reimbursements in Europe and the US. Immunovia performs clinical validation studies for the commercialization of IMMray™ PanCan-d, which may be the first blood-based test for early diagnosis of pancreatic cancer.

  • PR Newswire11 months ago

    Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston

    A highly skilled team with a proven track record of successfully establishing and scaling up CLIA accredited reference laboratories based on ground breaking new technologies have been recruited to carry out the US market introduction of Immunovia's first test, IMMray™ PanCan-d, in the second half of 2018. Mats Grahn, CEO Immunovia, comments: "The market introduction of IMMray™ PanCan-d, our blood based test for earlier detection of pancreas cancer, is the main focus for Immunovia.